PTGS2 and prostate carcinoma: Pretreatment of prostate cancer cells with the COX-2 inhibitor the EP4 antagonist, or the mTORC inhibitor significantly downregulated 8-CPT-2Me-cAMP-induced expression of p-cPLA2, COX-2, (Figure 4) S6-kinaseT389 (Figure 5) and p-AktS473 (Figure 6).